Q2 2023 Earnings Presentation

Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP income from operations" is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) 0000 Three Months Ended December 31, Six Months Ended 2022 December 31, December 31, 2021 2022 December 31, 2021 GAAP income from operations $ 280,194 $ Amortization of acquired intangibles-cost of sales (A) 7,305 248,711 $ 11,231 555,932 $ 13,680 510,624 22,289 Amortization of acquired intangibles-operating expenses (A) 9.563 7,738 17,513 15,445 Acquisition-related expenses (A) Non-GAAP income from operations 8,412 $ 305,474 $ 267,680 $ 9,157 596,282 $ 548,358 Note regarding non-GAAP reconciliations (A) ResMed adjusts for the impact of the amortization of acquired intangibles, acquisition-related expenses, and the reserve for disputed tax positions from their evaluation of ongoing operations and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non- GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 16 2023 ResMed | Q2 2023 Earnings Presentation - Jan. 26, 2023 ResMed

View entire presentation